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ABSTRACT
Background: The UK Health Technology Assessment (HTA) program
funds trials that address issues of clinical and cost-effectiveness to meet the
needs of the National Health Service (NHS). The objective of this review
was to systematically assess the methods of resource use data collection
and costing; and to produce a best practice guide for data capture within
economic analyses alongside clinical trials.
Methods: All 100 HTA-funded primary research papers published to June
2009 were reviewed for the health economic methods employed. Data
were extracted and summarized by: health technology assessed, costing
perspective adopted, evidence of planning and piloting, data collection
method, frequency of data collection, and sources of unit cost data.
Results: Ninety-ﬁve studies were identiﬁed as having conducted an eco-
nomic analysis, of which 85 recorded patient-level resource use. The
review identiﬁed important differences in how data are collected. These
included: a priori evidence of analysts having identiﬁed important cost
drivers; the piloting and validation of patient-completed resource use
questionnaires; choice of costing perspective; and frequency of data col-
lection. Areas of commonality included: the extensive use of routine
medical records and reliance on patient recall; and the use of standard
sources of unit costs.
Conclusion: Economic data collection is variable, even among a homoge-
neous selection of trials designed to meet the needs of a common organi-
zation (NHS). Areas for improvement have been identiﬁed, and based on
our ﬁndings and related reviews and guidelines, a checklist is proposed for
good practice relating to economic data collection within clinical trials.
Keywords: clinical trials, cost analysis, economic evaluation, health tech-
nology assessment.
Background
Economic evaluations have become increasingly integral to late-
phase clinical trials. Data generated from such trials can provide
unbiased estimates for the calculation of cost-effectiveness to
inform decisions on the effective and efﬁcient use of health care
resources. In the UK, the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) program funds
research, including clinical trials, to investigate the clinical and
cost-effectiveness of a range of health technologies (e.g., medi-
cines, devices, procedures, and screening) used to promote
health, prevent and treat disease, and improve rehabilitation and
long-term care [1]. The program is “needs-led” in that it priori-
tizes research projects for commissioning based on: the antici-
pated beneﬁts of reducing uncertainty (speciﬁcally in relation to
health outcomes, cost-effectiveness, and targeting of services), the
timescale for realizing beneﬁts, the importance of early assess-
ment (speciﬁcally in relation to the costs associated with not
doing the research), and other factors such as national priorities
and prevalence of the disease. Research ﬁndings, which are pub-
lished in the HTA’s own peer-reviewed journal, Health Technol-
ogy Assessment [2], have a bearing on clinical practice within the
National Health Service (NHS) directly, and indirectly, via guid-
ance issued by the National Institute of Health and Clinical
Excellence (NICE), as well as internationally.
Essential to any trial-based economic evaluation is a robust
method for collecting data on resource use. Nevertheless, there
are no universally recognized methods for economic data collec-
tion in HTA-funded trials, although a wide variety of techniques
are recognized and used. These methods include: patient self-
report (by questionnaire, interview, diary cards); use of routinely
available data (e.g., medical records and general practitioner
(GP) records); and use of expert panels. Each method has its
advantages and disadvantages. Reliance on patients, for instance,
is the most common approach, but is limited by biases in recall,
nonresponse, and evasiveness [3]. The use of routinely collected
data depends on accurate recording and information technology
infrastructure. Eliciting expert opinion is convenient, but is not
generally considered as a reliable or unbiased method of resource
use estimation.
There are several published reviews and good practice guide-
lines of economic evaluations within clinical trials [4–6];
however, the variability in the methods for resource use data
collection suggests a need for a standardized approach. Such a
guideline should also extend to the piloting and validation of
data collection instruments.
The aim of this review was to systematically assess the
methods of resource use data collection and costing of published
HTA-funded primary research studies, and to produce a best
practice guide for future studies.
Methods
All 100 studies published to June 2009 and classed as “primary
research” were identiﬁed from the Health Technology Assess-
ment journal [2]. The original articles containing a health eco-
nomic assessment (95 of 100) were obtained and reviewed by
CHR, with particular attention being paid to chapters, sections,
and appendices on economic analysis and data collection meth-
odology. Each article was also searched electronically for the key
words “perspective,” “viewpoint,” “questionnaire,” “forms,”
“resource,” “notes,” “interview,” “diary,” “cost,” “Netten,”
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“BNF,” “schedule,” “pilot,” “resource,” “valida,” “consult,”
“baseline,” “horizon,” and “economic.” Appendices were exam-
ined for copies of questionnaires and reference to relevant sec-
tions of case report forms. For each article reviewed, data
relating to the following ﬁelds were extracted:
1. Health technology being assessed;
2. Perspective adopted;
3. Methods for identifying items for costing;
4. Methods for piloting and validation of resource use data
collection instrument;
5. Resource use data collection methods;
6. Timing of data collection in relation to the trial duration;
7. Sources of unit costs.
A sample of data extractions was reviewed for accuracy by
DAH. Extracted data are summarized and a descriptive analysis
is presented.
Results
Ninety-ﬁve of the published HTA studies reported an economic
evaluation. The majority (75) was experimental in nature; 18
were observational and comprised of cohort, cross-sectional, and
case studies; and the remainder were nontrial-based economic
analyses. Randomized controlled trials made up the bulk of the
experimental group (73 of 75), whereas the other two were
randomized crossover trials. All of the ﬁve categories of health
technologies were assessed: procedures (37 of 95); devices (14);
drugs (13); screening (8); setting of care (1); and combinations of
the ﬁve (22). Studies included in the review are
listed in the Appendix (http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Hughes.asp). A summary of the
data extracted from each study is presented in Table 1.
Perspective
The choice of the perspective of an economic evaluation dictates
the resource items that are to be costed. There were no ﬁxed
protocols adhered to when deﬁning the perspective, although
nine studies referred to various guidelines [7–9] to support their
choice. As expected, all 95 studies included an NHS perspective;
21 also included Personal Social Service (PSS) costs, and 26
included costs to the NHS and patients. Seven studies were
identiﬁed that assessed costs to each group. The term “societal
perspective” was used frequently, but did not seem to be well
deﬁned. For example, some studies which reported a societal
perspective would in fact have been better described as having
adopted an NHS and patient perspective [10–12].
Planning and Piloting
Less than a quarter of studies (22 of 95) demonstrated any
evidence that a systematic approach had been followed for
resource identiﬁcation at the planning stage. Where evidence was
presented, this was usually done by consulting with health-care
professionals or conducting a review of published economic lit-
erature. The majority of the studies (85 of 95) captured patient-
level health-care resource use. Nevertheless, only 28 (of the 85)
studies reported validating their health-care resource use data
collection methods; and in only 21 of the 57 studies which used
patient- or carer-completed questionnaires or diaries was there
evidence of piloting. Methods for piloting varied widely—from
adopting formats that had been piloted in previous similar [13],
or even dissimilar [14] studies, to asking two carers to test a
resource use diary [15]. Health-care resource use data collection
methods were validated usually by comparing resource use data
questionnaire content with routinely collected data sources such
as GP notes [16,17] and hospital records [18,19].
Methods for Data Collection
For the purpose of the review, the methods used to capture
patient-level data have been categorized as follows:
1 Medical records taken from routine primary and secondary
care sources (e.g., patient notes, databases);
2 Prospective forms completed by trial researchers or health-
care professional (not based on patient recall or abstracted
from routine sources);
3 Prospective forms completed by trial researchers or health-
care professional (based on patient recall);
4 Patient or carer-completed diaries (carer in this context
meaning nonhealth-care professional);
5 Patient-completed or carer-completed forms.
A majority of the studies (61 of the 85) used at least two
methods, typically involving patient- or carer-completed form
and medical records. Fifty-nine studies relied on medical records,
and 48 used patient- or carer-completed forms. Prospective
methods based on patient recall were reported in 23 of the 85
studies. A similar number (22) was found for prospective
methods that were not associated with patient recall or based on
data abstracted from medical records. Patient- or carer-
completed diaries were used in 20 studies. Taking into account
the overlap of methodologies, 63 studies used nondiary-based
patient recall (involving one or more of: patient-completed
forms, carer-completed forms, or prospective methods such as
face-to-face interview). Forty-three of these 63 trials supple-
mented methods based on patient recall, with data from other
routine sources such as GP records, hospital notes, and hospital
databases. Only 14 of these, however, used routine data to
capture the same data as recorded by questionnaire.
Frequency of Data Collection
Trial durations (patient study period, as opposed to overall
length of trial) within the 85 HTA studies that include a patient-
level economic evaluation, ranged from a few days to 15 years,
reﬂecting the nature of the health technology being assessed. The
timing of resource use data collection in relation to the trial
duration could not be determined in 6 of the 85 studies. Baseline
economic data were measured in 51 studies. This usually
involved either administering a baseline questionnaire to measure
resource use prior to or at the index procedure, or a retrospective
data extraction from patient records.
Between baseline and end of study, the favored time for
resource use data collection fell in the last quarter of the trial
duration (50 of 79 cases) and the least favored fell in the third
quarter (17). First and second quarter data collections occurred
at similar frequencies (37 and 35, respectively).
Unless otherwise speciﬁed, we deﬁned the recall periods in
the 63 studies that involved patient-, carer-, and researcher-
completed forms (not diaries) as the time since the previous recall
questionnaire where one existed, or otherwise, deﬁned as the
time between randomization and the ﬁrst questionnaire. Using
this deﬁnition, 55 studies in which recall periods could be esti-
mated (of the 63), yielded a total of 121 recall periods. Median
recall period was 4.5 months (interquartile range, 2 to 6 months).
The median number of recall-based questionnaires deployed per
patient in each of the 55 studies was 2 (interquartile range, 2 to
3).
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Sources of Unit Cost Data
Studies were reliant on a limited number of primary sources of
unit costs. The annual compendium of Unit Costs of Health and
Social Care by Netten & Curtis [20] was used extensively (72 of
95 economic studies). Drug costs were included in 57 of the 95
economic studies. They were for the most part taken from the
British National Formulary [21], a biannual publication that
reports prices that are calculated from the net cost used in pricing
NHS prescriptions dispensed in the previous year. Two studies
referred to the Monthly Index of Medical Specialties [22], which
sources generic drug costs from the Drug Tariff [23] (a monthly
publication compiled on behalf of the Department of Health by
the NHS Prescription Pricing Division) and branded medicines
from manufacturers. Seven studies referred to the Drug Tariff
directly.
Fifty-two economic evaluations used unit costs that had been
sourced locally. These were mostly provided by NHS Trusts,
although local councils were sometimes used [24] as were other
miscellaneous local sources such as acupuncturists [14,25] and
medical herbalists [14]. Thirty-six of the 95 evaluations used
health-care resource groups (HRGs). These are a secondary
health-care classiﬁcation of groups of procedures and treatments
that are clinically meaningful and are expected to use similar
amounts of resource. They are generated from the content of the
patient record and use a combination of administration, proce-
dure, and diagnoses primary classiﬁcations to describe the care
received by a patient [26]. A large number of secondary sources
of unit costs were also used by analysts to value resources. These
included national pay scales, prices provided by vendors, costs
published by the Chartered Institute of Public Finance &
Accountancy, and estimates derived from published studies.
Discussion
Published guidelines and reviews on the conduct of economic
evaluations alongside clinical trials outline the available methods
for estimating health-care resource use, and sources of unit costs
[4,5,27]. Nevertheless, they offer no standard methodology, and
as a consequence, this introduces important differences in how
such data are collected [28]. This is evident even among the
homogeneous selection of trials (i.e., UK NIHR HTA-funded)
that address the needs of a common organization (NHS) included
in the present review. In line with HTA’s remit of generating
high-quality research on the effectiveness, costs, and broader
impact of health technologies, almost all (95%) clinical trials
contain an economic analysis. An important consideration in any
trial-based economic evaluation, however, is the external validity
of the results. Not all trials are suitable as a vehicle for economic
analyses, and not all economic questions can be addressed
adequately through trial-based evaluation. Trials are often
limited by, for instance, being insufﬁcient in duration of follow-
up, not including all relevant comparators, and being selective in
terms of inclusion and exclusion criteria. Consequently, results
may not always be generalizable, and trial-based assessments are
increasingly being viewed as one component of a broader frame-
work of evidence synthesis and decision analysis [29]. Although
HTA-funded trials are generally pragmatic in design—to address
issues of effectiveness as opposed to efﬁcacy—the appropriate-
ness (or otherwise) of conducting an economic evaluation for all
the health technologies evaluated was not assessed in our review.
We considered this unlikely to have an impact on the methods
employed for the collection of resource use data although
acknowledge the potential impact on the interpretation of the
results of the analyses.
Our review has revealed some areas of commonality in the
methods used. These include: the extensive use of routine medical
records, reliance on patient recall, and the use of standard
sources of unit costs. Nevertheless, there were also important
differences in health economists’ approaches to resource costing.
Analysts’ choice of perspective was without full explanation in
many instances, although this might be expected given that all
studies address areas of priority for the NHS. Nevertheless, this
might still have a signiﬁcant impact on the estimation of cost-
effectiveness, and relevance to decision makers. Theoretically, the
correct perspective should be the one that takes into account the
costs and beneﬁts of the intervention, no matter on whomsoever
they should fall [30]—such a holistic perspective is by deﬁnition
a societal one. In practice, societal perspectives will usually be
relevant when a patient has complex needs that extend beyond
the scope of primary or secondary health-care providers and PSS
to include, for instance, social security and housing beneﬁt;
criminal justice; education; patient and their families; and lost
production. Despite this, HTA studies usually adopt an NHS
perspective. Some studies also included PSS, patient, and/or a
poorly-deﬁned “societal” perspective, which might have conse-
quences if costs and beneﬁts were to accrue outside of the chosen
area [30,31]. This is in line with the NICE guideline on the
methods of technology appraisal [8], which recommends that
costs should be taken from the perspective of the NHS and PSS
but also accept—in exceptional circumstances—analyses where
some costs (or cost savings) fall outside of this perspective. The
choice of appropriate perspective is still a matter of ongoing
debate for health economic analysis [32]. Within the United
Kingdom, further consideration should also be given to regional
variations—whereas the NHS and PSS are ﬁnanced separately in
England and Scotland, they are within the same government
departments in Wales and Northern Ireland.
Evidence that a systematic approach had been followed for
resource identiﬁcation at the planning stage (e.g., pilot study,
systematic review of relevant literature, expert opinion) was
present in a minority of studies. It is important to conduct these
exercises not just to identify the main cost-driving events associ-
ated with a health technology, but also to assess which baseline
cost data are required, and what data are needed to maximize
external validity.
Piloting of data collection instruments is fundamental to
ensuring their reliability [6], although there is little in the way of
standard methodology with respect to the collection of resource
data, and widespread practice is not evident. Validation of data
collection instruments is an important procedure for accurate
data capture. Studies identiﬁed in the present review that
reported methods for validation used the following techniques:
1. Questionnaire responses compared to routinely collected
data such as hospital notes. One study, for instance, vali-
dated through triangulation by comparison of GP notes,
patients’ responses to questionnaire, and hospital notes
[33].
2. Prevalidation from previous literature or pilot studies (e.g.,
Client Service Receipt Inventory [34]).
3. Validation using combined data from electronic systems
(e.g., condition-speciﬁc databases checked against GP
records and hospital admissions database [35]).
The use of questionnaires based on patient recall was found
to be the most variable aspect of the HTA trials studied. Fifty-
nine of 121 recall periods covered time spans of 6 months or
greater. This is one potential source of bias in methods of patient/
carer self-reported health-care resource use. Richards et al. [36]
reported that older patients tend to underestimate resource use
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compared with health providers even within relatively short time
frames. A second source of bias relates to completeness. Mistry
et al. [37] reported that missing items from patient-completed
questionnaires tended to force reliance on GP records. Other
methods of acquiring resource use data are not without their
limitations either. Byford et al. [38], for instance, showed that GP
records are unreliable for gathering nonpractice-based health
service data (e.g., hospital and community health services).
There is a range of conceptual approaches to costing. In
addition to gross-costing and microcosting methodologies,
bottom-up microcosting and top-down microcosting have been
described [39]. The bottom-up microcosting method is charac-
terized by the identiﬁcation of patient-speciﬁc resource use and
hospital-speciﬁc unit costs. It has been proposed as the gold
standard in hospital service costing methodology but is consid-
ered very time-consuming and best suited to the main cost
drivers. Top-down microcosting is characterized by the identiﬁ-
cation of patient-speciﬁc resource use and national tariffs as unit
costs. This is the favored methodology in the HTA trials as
national tariffs are more readily available than local unit costs
and are more generalizable across the NHS.
The use of routinely collected data has been made increas-
ingly possible with advances in information technology. Hospital
electronic database systems, for instance, when used in tandem
with routine electronic patient administration systems, may go
some way toward making hospital-speciﬁc unit costs more acces-
sible. A further NHS development in England (but not elsewhere
in the United Kingdom) has been Payment by Results (PbR), a
means of paying health-care providers a ﬁxed price for each
individual case treated [40]. The currency of patient resource use
associated with PbR is the HRG. Patient-speciﬁc HRGs are avail-
able as extracts from the NHS Information Centre [41] and
routine data will be made available to health economists using
multiple-linked databases through the development of a Health
Research Support Service [42]. Another ongoing development in
England is the NHS Care Records Service [43] which will com-
prise of detailed records containing patient-level information on
both primary and secondary care. The availability of such
routine data for research purposes should be exploited but
because of the uncertainty as to which data collection method is
the most accurate, we recommended that more than one tech-
nique be used to measure those resources that contribute the
most to the overall cost.
Conclusion
The review indicates variable practice in economic data collec-
tion in published HTA-funded trials. Areas for improvement
have been identiﬁed and, based on our ﬁndings and related
reviews and guidelines, we propose a checklist for good practice
relating to economic data collection within clinical trials
(Table 2).
Source of ﬁnancial support: Funded by the Medical Research Council, as
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Table 2 Good practice checklist for resource use data capture alongside HTA clinical trials
Practice Recommendation
Perspective Should be aligned with that of the decision maker (e.g., NHS and /or Personal Social Services, multi-agency public sector,
societal).Avoid inappropriate use of the phrase “societal perspective.”
Identify resources for
measurement
Items for costing should be identiﬁed a priori from consultation with health-care professionals, pilot studies, or literature
searches. It is important to identify the expected main cost-driving events and to justify the range of resource items that
are to be valued. Issues for consideration: (i) What are the consequences of not collecting these data?; (ii) What
information is available on the key events within the study?; (iii) Which baseline data are needed?; (iv) What data are
needed to maximize external validity?; (v) Protocol-driven resource use should be identiﬁed, and adjusted for, accordingly.
Data collection/analysis plan A plan detailing how cost and resource use data will be obtained is essential—paying particular attention to: (i) the
frequency of resource data collection; (ii) identifying if data collection needs to be resource-, effects- or schedule-driven
[6]; (iii) considering whether the methods of resource use data collection will impact on the trial outcome (e.g., diaries
may improve adherence to intervention); (iv) single-site or multi-site sources; (v) the time horizon within which resource
use data are needed; (vi) statistical analysis.
Resource use data collection The choice depends on the balance between factors that include: (i) reliability of patient recall; (ii) burden on the researcher/
health-care practitioner; (iii) completeness and appropriateness of routinely collected data; (iv) information technology
systems; and (v) the cost of research (i.e., acquiring the data).The method selected, and frequency of data capture, should
be informed by previous studies or pilot studies [4].
Baseline cost data Should be collected as an important predictor of future costs. In studies with a small sample size, baseline characteristics
need to be balanced [44]. Costs can be adjusted for baseline differences for example by use of appropriate
regression-based modelling.
Piloting Patient-/carer-completed forms should be piloted to test clarity, ease of use and completion rates [11]. Piloting is also useful
in determining the main cost-driving events related to the health technology.
Validation Where possible, alternative methods of resource use data collection should be employed to test for validity [28,37].
Non-trial estimates of
resource use
If nontrial resource use estimates are used to supplement trial-based data, there needs to be a documented and systematic
approach to their selection. Resources used as a result of the trial protocol should be excluded.
Method of costing Top-down microcosting, applying national costs to patient-level units of resource use where they exist.This increases
generalizability.
Unit costs Valued using national costs for the most recently available year [7]. If national costs do not exist for items of resource use,
apply unit costs sourced locally.
Standardized reporting format A common reporting format for economic evaluations would improve transparency and enhance benchmarking between
similar studies [45].
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